Clinical Trials Sponsored by Pieris Pharmaceuticals GmbH

Total 281 results

Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Phase 2a Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Czechia, Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Unknown

Phase Ib Study to Evaluate PRS-080 in Anemic Chronic Kidney Disease Patients

Anemia of Chronic Kidney Disease

Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH

Completed

Study of Angiocal® in Patients With Solid Tumors, Investigating Safety, Tolerability, Blood Concentration of Study Drug

Solid Tumor

Germany
Pieris Pharmaceuticals GmbH
FGK Clinical Research GmbH; Nuvisan Pharma Services; EUROCALIN Consortium

Completed

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PRS-080

Healthy

Germany
Apurano Pharmaceuticals GmbH

Recruiting

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Diabetic Polyneuropathy

Pain | Diabetes | Diabetic Neuropathies | Chronic Pain | Peripheral Neuropathy | Pain, Chronic | Chronic Pain Syndrome | Diabetic Polyneuropathy | Pain Syndrome | Peripheral Neuralgia | Peripheral Neuropathy With Type 2 Diabetis

Germany
Apurano Pharmaceuticals GmbH

Recruiting

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Central Neuropathy of Any Genesis

Stroke | Pain | Multiple Sclerosis | Chronic Pain | Traumatic Brain Injury | Neuropathic Pain | Pain, Chronic | Chronic Pain Syndrome | Paraplegia | Phantom Pain | Pain Syndrome | Central Neuropathic Pain | Phantom Limb Syndrome With Pain

Germany
Apurano Pharmaceuticals GmbH

Recruiting

Efficacy and Tolerability of AP707 in Patients With Chronic Pain Due to Traumatic or Post-operative Peripheral Neuropathy

Pain | Chronic Pain | Neuropathic Pain | Peripheral Neuropathy | Pain, Chronic | Post Operative Pain | Chronic Pain Syndrome | Pain Syndrome | Peripheral Nerve Injury | Post-Traumatic Neuralgia | Peripheral Neuralgia | Plexopathy

Germany
Cardior Pharmaceuticals GmbH

Not yet recruiting

Reverse Remodeling Effects of CDR132L in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy (REMOD-REVERT)

Heart Failure With Preserved Ejection Fraction
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines (ULTRA I)

Moderate to Severe Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines, and Lateral Canthal Lines)

United States
Merz Pharmaceuticals GmbH

Completed

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy (XARA)

Cerebral Palsy | Spasticity

Poland, Russian Federation, Ukraine, United States, Argentina, Mexico
Merz Pharmaceuticals GmbH

Completed

Botulinum Toxin A to Treat Arm Tremor

Essential Tremor of the Upper Limbs

United States, Canada
Merz Pharmaceuticals GmbH

Completed

Evaluation of the Sensitivity of Merz Lips Fullness Assessment Scale Following Etermis 4® Treatment for Lips Volume Augmentation (ELISE)

Subjects Desiring Lip Augmentation

Germany
Merz Pharmaceuticals GmbH

Completed

Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions (SIAXI)

Parkinson's Disease | Traumatic Brain Injury | Chronic Troublesome Sialorrhea | Post-stroke

Germany, Poland
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Abnormal Contraction or Twitch of the Eyelid

Bilateral Blepharospasm (BEB)

Greece, Malaysia, Sri Lanka
Merz Pharmaceuticals GmbH

Completed

Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy

Lower Limb and Combined Lower Limb and Upper Limb Spasticity Due to Cerebral Palsy

Poland, Austria, Czechia, Estonia, Germany, Israel, Korea, Republic of, Romania, Russian Federation, Slovakia, Turkey, Ukraine
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm

Spasticity of the Upper and Lower Limb Due to Cerebral Causes

Germany, United States, Canada, France, Italy, Norway, Portugal, Spain
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus (EASE)

Subjective Tinnitus

Germany, Portugal, Spain, United Kingdom, Austria
Merz Pharmaceuticals GmbH

Completed

Effectiveness and Safety Study of Overnight Intensive Patch in Scars

Post Dermatological Surgery Scars

Germany
Merz Pharmaceuticals GmbH

Withdrawn

Effect of NT 201 (Botulinum Neurotoxin Type A Free of Complexing Proteins) on Sleep-related Breathing Disorders (Snoring)

Sleep-Disordered Breathing
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety of NT 201 in the Treatment of Lateral Periorbital Wrinkles

Lateral Periorbital Wrinkles

France, United Kingdom, Germany, Italy
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Moderate to Severe Glabellar Frown Lines

United States
Merz Pharmaceuticals GmbH

Completed

Evaluation of Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of Neramexane Mesylate in Healthy Japanese Subjects

Healthy

United States
Merz Pharmaceuticals GmbH

Completed

Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects

Healthy Subjects

Germany
Merz Pharmaceuticals GmbH

Completed

A Single Center, Open-Label Study to Quantify Metabolites of [14C]-Neramexane in Plasma and Urine in Healthy Male Subjects

Metabolism of Neramexane

Belgium
Merz Pharmaceuticals GmbH

Completed

Open, Single Center, Three Periods, Fixed Sequence Design Study on the Effects of Clopidogrel Co-administration on the Pharmacokinetics of Neramexane

Healthy Subjects

Germany
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus

Nystagmus, Acquired | Nystagmus, Congenital Idiopathic

United Kingdom
MerLion Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Finafloxacin Used in Helicobacter Pylori Infected Patients (FLASH)

Dyspepsia | Gram-Negative Bacterial Infections | Helicobacter Infections

Germany
MerLion Pharmaceuticals GmbH

Terminated

First Time in Man Trial for Friulimicin B

Staphylococcal Skin Infections | Community Acquired Pneumonia

Switzerland
Apurano Pharmaceuticals GmbH

Recruiting

Long Term Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Pain | Lower Back Pain | Back Pain | Chronic Pain | Pain, Chronic | Chronic Pain Syndrome | Pain Syndrome | Lower Back Pain Chronic

Germany
Apurano Pharmaceuticals GmbH

Recruiting

Efficacy and Tolerability of AP707 in Patients With Chronic Back Pain

Pain | Lower Back Pain | Back Pain | Chronic Pain | Pain, Chronic | Chronic Pain Syndrome | Pain Syndrome | Lower Back Pain Chronic

Germany
Merz Pharmaceuticals GmbH

Recruiting

Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury (PATTERN)

Lower Limb or Combined Lower Limb and Upper Limb Spasticity Due to Stroke or Traumatic Brain Injury

United States, Belgium, Czechia, France, Italy, Poland, Spain, Switzerland, United Kingdom, Australia, Germany, Hungary, Norway, Slovakia, Ukraine, Russian Federation
Cardior Pharmaceuticals GmbH

Active, not recruiting

Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction (HF-REVERT)

Myocardial Infarction, Acute | Heart Failure, Left Sided

Netherlands, Spain, Hungary, Germany, United Kingdom, Czechia, Poland, Greece
Merz Pharmaceuticals GmbH

Completed

Clinical Study to Investigate the Efficacy and Safety of NT 201 Compared to Placebo in the Treatment of Chronic Troublesome Drooling Associated With Neurological Disorders and/or Intellectual Disability (SIPEXI)

Stroke | Cerebral Palsy | Intellectual Disability | Traumatic Brain Injury | Chronic Troublesome Sialorrhea

Georgia, Hungary, Poland, Russian Federation, Serbia, Ukraine
Merz Pharmaceuticals GmbH

Completed

Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy

Lower Limb Spasticity Due to Cerebral Palsy

Poland, Austria, Czechia, Estonia, France, Germany, Israel, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Turkey, Ukraine
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines

Glabellar Lines

United States, Germany, Canada
MerLion Pharmaceuticals GmbH

Completed

Pharmacokinetic Profile in Plasma and Epithelial Lining Fluid of Finafloxacin

Safety and Tolerability

United States
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke (PURE)

Post-stroke Spasticity of the Upper Limb

Poland, United States, Czech Republic, Germany, Hungary, India, Russian Federation
Merz Pharmaceuticals GmbH

Completed

Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke (PLUS)

Post-stroke Spasticity of the Lower Limb

Germany, Poland, Spain, United States, Czech Republic, Russian Federation, Canada, France, Italy
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia

Cervical Dystonia

United States
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm

Blepharospasm

United States, Canada
Merz Pharmaceuticals GmbH

Completed

Memantine and Validation of a New Alzheimer's Disease Scale

Alzheimer's Disease

Germany
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Subjective Tinnitus

United States, Austria, Germany, Brazil, Mexico
Merz Pharmaceuticals GmbH

Completed

Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines

Healthy

Germany
Merz Pharmaceuticals GmbH

Terminated

Blepharospasm Short Interval

Blepharospasm

Germany
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

Germany
Merz Pharmaceuticals GmbH

Terminated

Memantine and Antipsychotics Use (MemAP)

Alzheimer's Disease

Germany
Merz Pharmaceuticals GmbH

Completed

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines

Glabellar Frown Lines

Germany
Merz Pharmaceuticals GmbH

Completed

Study Analyzing the Effect of Rifampicin Administration on the Pharmacokinetics of Neramexane Mesylate

Healthy

Germany
Merz Pharmaceuticals GmbH

Completed

IncobotulinumtoxinA (Xeomin) for Upper Limb Spasticity (NT-Spin)

Upper Limb Spasticity

France, Spain, Switzerland, United Kingdom, Italy, Austria, Germany, Portugal
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

Subjective Tinnitus

Belgium, Czech Republic, France, Poland, South Africa, Netherlands

Clinical Trials Sponsored by Pieris Pharmaceuticals GmbH

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uruguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations